{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:22:02Z","timestamp":1773796922200,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1127","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BJR"],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:sec><jats:title>Objective:<\/jats:title><jats:p> The most commonly used dose for prostate cancer stereotactic body radiotherapy (SBRT) is 5 \u00d7 7.25\u2009Gy. The aim of this study was to evaluate the dosimetric feasibility of a 5 \u00d7 9\u2009Gy SBRT regimen while still limiting the dose to the urethra to 5 \u00d7 7.25\u2009Gy. This dosimetric study is part of the groundwork for a future Phase III randomized trial. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> The prostate, the urethra and the tumors were delineated on 20 dosimetric CT-scans with MRI-registration. The planning target volume (PTVp) was defined as a 5\u2009mm expansion (3\u2009mm posteriorly) of the prostate. The planning at risk volume (PRVu) was defined as a 2\u2009mm expansion of the urethra. The tumors were delineated on the MRI (GTVt) and a 3 mm-margin was added to create a tumoral planning target volume (PTVt). IMRT plans were optimized to deliver 5 \u00d7 9\u2009Gy to the PTVp, limiting the dose to the PRVu to 5 \u00d7 7.25\u2009Gy. Results are presented using average (range) values. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> PTVp doses were D98% = 36.2\u2009Gy (35.6\u201336.8), D2% = 46.9\u2009Gy (46.5\u201347.5) and mean dose = 44.1\u2009Gy (43.8\u201344.5). The dose to the PRVu was within tolerance limits for all 20 patients: V34.4Gy = 99.8% (99.2\u2013100) and D5% = 38.7\u2009Gy (38.6\u201338.8). Dose coverage of PTV-PRVu was D95% = 40.6\u2009Gy (40.5\u201340.9), D5% = 46.6\u2009Gy (46.2\u201347.2) and mean dose = 44.6\u2009Gy (44.3\u201344.9). Dose to the PTVt reached 44.6\u2009Gy (41.2\u201345.9). Doses to the OAR were respected, except V36Gy \u22641\u2009cc for the rectum. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> A SBRT dose-escalation to 5 \u00d7 9\u2009Gy on the prostate while sparing the urethra + 2\u2009mm at 36.25\u2009Gy is feasible without compromising dose coverage to the tumor. This radiation regimen will be used for a Phase-III trial. <\/jats:p><\/jats:sec><jats:sec><jats:title>Advances in knowledge:<\/jats:title><jats:p> In prostate SBRT, dose optimization on the urethra is feasible and could decrease urinary toxicities. <\/jats:p><\/jats:sec>","DOI":"10.1259\/bjr.20210142","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T17:01:10Z","timestamp":1626800470000},"source":"Crossref","is-referenced-by-count":3,"title":["Dosimetric feasibility of stereotactic irradiation of primary prostate cancer at 5x9 Gy with a method of urethral sparing"],"prefix":"10.1093","volume":"94","author":[{"given":"Salim","family":"Benhmida","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Beneux","sequence":"additional","affiliation":[{"name":"Department of Medical Physics and Radioprotection, Centre Hospitalier Lyon Sud, Pierre Benite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Udrescu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Rouviere","sequence":"additional","affiliation":[{"name":"Department of Urological Radiology, Hopital Edouard Herriot, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samy","family":"Horn","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ciprian","family":"Enachescu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Lapierre","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Chapet","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Centre Hospitalier Lyon Sud, Pierre Benite, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.03.051"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2017.02.006"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.11.054"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.12.045"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.014"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.01.092"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-8-58"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00122"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.10.039"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30569-8"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.09.028"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.08.007"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.09.007"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2966"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2020.06.002"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-82"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179845"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.03.012"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1346-5"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.birpublications.org\/doi\/pdf\/10.1259\/bjr.20210142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T16:40:58Z","timestamp":1705077658000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/7451714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":19,"journal-issue":{"issue":"1127","published-print":{"date-parts":[[2021,11,1]]}},"alternative-id":["10.1259\/bjr.20210142"],"URL":"https:\/\/doi.org\/10.1259\/bjr.20210142","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"article-number":"20210142"}}